Clinical Trials Browser

Phase 2 × Recruiting × BRCA-Mutated Breast Carcinoma × Clear all

NCT06516289 2024-12-12

Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

Phase 2 Recruiting

BRCA-Mutated Breast Carcinoma